Insider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 4,300 Shares of Stock

CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 4,300 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $10.21, for a total value of $43,903.00. Following the completion of the sale, the director now owns 90,000 shares of the company’s stock, valued at $918,900. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kurt Von Emster also recently made the following trade(s):

  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.41, for a total value of $1,629,736.72.
  • On Friday, November 10th, Kurt Von Emster sold 50,048 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.26, for a total value of $463,444.48.
  • On Tuesday, October 31st, Kurt Von Emster sold 59,209 shares of CymaBay Therapeutics stock. The shares were sold at an average price of $9.27, for a total value of $548,867.43.

CymaBay Therapeutics Inc (NASDAQ:CBAY) opened at $9.91 on Friday. CymaBay Therapeutics Inc has a 12 month low of $1.46 and a 12 month high of $10.25. The stock has a market capitalization of $434.69, a PE ratio of -9.81 and a beta of 1.82. The company has a quick ratio of 7.39, a current ratio of 7.39 and a debt-to-equity ratio of 0.04.

CymaBay Therapeutics (NASDAQ:CBAY) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same period in the previous year, the firm posted ($0.25) earnings per share. research analysts anticipate that CymaBay Therapeutics Inc will post -0.82 EPS for the current year.

Several large investors have recently made changes to their positions in CBAY. Bank of New York Mellon Corp raised its stake in shares of CymaBay Therapeutics by 0.8% in the second quarter. Bank of New York Mellon Corp now owns 17,344 shares of the biopharmaceutical company’s stock worth $100,000 after purchasing an additional 140 shares during the last quarter. Marshall Wace North America L.P. purchased a new position in shares of CymaBay Therapeutics in the second quarter worth about $242,000. Ardsley Advisory Partners raised its stake in shares of CymaBay Therapeutics by 66.2% in the second quarter. Ardsley Advisory Partners now owns 50,210 shares of the biopharmaceutical company’s stock worth $290,000 after purchasing an additional 20,000 shares during the last quarter. Boothbay Fund Management LLC purchased a new position in shares of CymaBay Therapeutics in the third quarter worth about $404,000. Finally, Crestline Management LP purchased a new position in shares of CymaBay Therapeutics in the third quarter worth about $841,000. Hedge funds and other institutional investors own 69.12% of the company’s stock.

A number of equities research analysts have commented on CBAY shares. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Piper Jaffray Companies reiterated a “buy” rating and issued a $12.00 price target on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research note on Wednesday, November 8th. Oppenheimer set a $15.00 price target on CymaBay Therapeutics and gave the company a “buy” rating in a research note on Monday, October 30th. Finally, Leerink Swann reiterated a “buy” rating and issued a $16.00 price target on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of $14.50.

COPYRIGHT VIOLATION WARNING: “Insider Selling: CymaBay Therapeutics Inc (CBAY) Director Sells 4,300 Shares of Stock” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.com-unik.info/2018/01/12/insider-selling-cymabay-therapeutics-inc-cbay-director-sells-4300-shares-of-stock.html.

CymaBay Therapeutics Company Profile

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

What are top analysts saying about CymaBay Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CymaBay Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit